A5067364699- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Research Studies
- PI3K/AKT/mTOR signaling in cancer
- Drug-Induced Adverse Reactions
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Pneumonia and Respiratory Infections
- Head and Neck Cancer Studies
- Eosinophilic Disorders and Syndromes
- Neuroendocrine Tumor Research Advances
- Acute Myeloid Leukemia Research
- Infective Endocarditis Diagnosis and Management
- Inflammatory Myopathies and Dermatomyositis
- Multiple and Secondary Primary Cancers
- Chemotherapy-related skin toxicity
- Antimicrobial Resistance in Staphylococcus
- Nonmelanoma Skin Cancer Studies
- Bladder and Urothelial Cancer Treatments
- Soft tissue tumor case studies
Hyogo Prefectural Cancer Center
2023-2024
Osaka City General Hospital
2022
Osaka Prefectural Medical Center
2022
Kobe City Medical Center West Hospital
2017-2021
Gifu Municipal Hospital
2021
Kobe Medical Center
2021
Kurashiki Central Hospital
2012-2019
There have been few data on the chemotherapy in elderly advanced non-small cell lung cancer (NSCLC) patients with poor performance status (PS), and usefulness of for such remains unclear. The objective this study was to identify factors that predicted survival benefit chemotherapy.All consecutive (≥75 years) NSCLC, Eastern Cooperative Oncology Group PS ≥2, EGFR mutation wild type/unknown, newly diagnosed from January 2009 December 2012 at a tertiary hospital were retrospectively reviewed.We...
Interstitial lung disease (ILD) associated with clinically amyopathic dermatomyositis (CADM-ILD) is often refractory and rapidly progressive. Although the anti-melanoma differentiation-associated gene 5 (anti-MDA-5) antibody progressive ILD (RP-ILD), differences in clinical features prognosis of anti-MDA-5 antibody-positive -negative CADM-ILD remain unclear.To clarify between cases, we retrospectively reviewed medical records patients diagnosed without at Kurashiki Central Hospital from...
Abstract Background Despite the wide-spread use of immune checkpoint inhibitors (ICIs) in cancer chemotherapy, reports on patients developing acquired resistance (AR) to ICI therapy are scarce. Therefore, we first investigated characteristics associated with shorter durable responses treatment and revealed clinical patterns AR prognosis involved. Methods We conducted a retrospective multi-center cohort study that included NSCLC PD-L1 tumor proportion scores ≥50% who received first-line...
Background Pembrolizumab is currently approved as a first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with programed death ligand-1 (PD-L1) expression ≥50%. However, the association between efficacy of pembrolizumab and PD-L1 levels in ≥50% has not been fully elucidated. Methods We retrospectively analyzed NSCLC tumor proportion score (TPS) who received at 11 institutions Japan February 2017 January 2018. Patients were divided into TPS 50–89% 90–100% (ultra-high...
Abstract Introduction Hypersensitivity reactions (HSRs) to chemotherapy are serious adverse events associated with cancer drug therapy and can occur any antitumor drug. This study investigated the safety efficacy of carboplatin desensitization in Japan established a method for treating HSRs. Methods Patients diagnosed gynecological (ovarian, endometrial, or cervical) cancers who underwent between 2016 2020 at Gynecologic Cancer Study Group Clinical Oncology were included. The each...
Abstract Background Pembrolizumab is effective as first-line therapy against advanced non-small cell lung cancer (NSCLC) in patients with programmed death ligand-1 (PD-L1) expression levels ≥50% [1]. However, it not all patients, and the factors predicting responses among this population remain unknown. Methods We retrospectively analyzed NSCLC a PD-L1 tumor proportion score (TPS) > 50%, who received monotherapy pembrolizumab from February 1, 2017 to April 30, 2018. The study included 11...
This report presents a case of fulminant community-acquired Pseudomonas aeruginosa necrotizing pneumonia in previously healthy young man, including an analysis the virulence P.aeruginosa isolated from patient. The patient was successfully treated with intensive care and antibiotic treatment. study analyzed pathogenicity strain both vivo (using mouse model) vitro biofilm production), but could not explain how otherwise man developed such severe pneumonia. Although rare pneumonia, infection...
<b><i>Background:</i></b> There has been no study so far on gemcitabine continuous maintenance therapy targeting only squamous non-small-cell lung cancer (NSCLC) patients. This aimed to assess the efficacy and safety of cisplatin plus followed by for chemotherapy- naïve Japanese patients with advanced NSCLC. <b><i>Methods:</i></b> The received 4 cycles (1,000 mg/m<sup>2</sup>, days 1 8) (80 day 1) every 3 weeks, alone as weeks until...
An 80-year-old man was admitted to the hospital because of fever, bloody sputum and exertional dyspnea 3 days. Laboratory tests showed anemia increase C-reactive protein level. A chest computed tomography scan revealed diffuse bilateral ground-glass opacities. Bronchoalveolar lavage confirmed clinical diagnosis alveolar hemorrhage (DAH). After methylprednisolone pulse therapy, Enterococcus faecalis detected in blood cultures. infective endocarditis made according Modified Duke's criteria....
e17631 Background: The purpose of the present study was to investigate real-world experience with carboplatin desensitization (CD) therapy in Japan, along its safety, and establish a strategy address carboplatin-induced hypersensitive reactions (HSRs). Methods: included patients diagnosed gynecologic cancer (ovarian, endometrial, or cervical cancer, i.e., OC, EC, CC, respectively) who underwent CD between 2016 2020 at Japan Clinical Oncology Group Gynecologic Cancer Study (JCOG-GCSG)...